Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-005000
Filing Date
2025-11-14
Accepted
2025-11-14 16:06:28
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9448
  Complete submission text file 0000902664-25-005000.txt   11252
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Subject) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90538 | Film No.: 251485917
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A